ARGOSMD, INC.

STUDIO CITY, CA

OncologyCAR-TGrant-only

What changed

Study registered, no phase assigned: Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial

3w agoTrial registeredJun 23, 2026Source filing (opens the source filing in a new tab)

Momentum

81no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Grant-only

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
NA registered
Jan 28, 2026
Lung Non-Small Cell Carcinoma · RECRUITING · sponsor: Fred Hutchinson Cancer Center · Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial
ClinicalTrials.gov · NCT06983899 (opens the source filing in a new tab)
Grant
K01 · $165k · non-dilutive
May 15, 2025
UNIVERSITY OF WASHINGTON · PI KANG, DAHYEON · NIAAA · award ends Apr 30, 2030 · Understanding the neural markers of incentive salience for alcohol: the role of context in brain-behavior relationships
NIH RePORTER · NIH RePORTER 11031607 (opens the source filing in a new tab)
Grant
R01 · $391k · non-dilutive
Feb 21, 2025
UNIVERSITY OF ARIZONA · PI KANG, DONGKYUN · NCI · award ends Jan 31, 2030 · Non-invasive, quantitative microscopic biomarkers for chemotherapy-induced peripheral neuropathy
NIH RePORTER · NIH RePORTER 11121422 (opens the source filing in a new tab)
Grant
R41 · $400k · non-dilutive
Feb 1, 2025
ARGOSMD, INC. · PI KANG, DONGKYUN · NCI · award ends Jan 31, 2027 · Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
NIH RePORTER · NIH RePORTER 11077184 (opens the source filing in a new tab)
Grant
R01 · $351k · non-dilutive
Jan 13, 2025
UNIVERSITY OF ARIZONA · PI KANG, DONGKYUN · NIBIB · award ends Dec 31, 2028 · Probe-Based Light Sheet Microscopy (pLSM) for Screening of Anal Cancer
NIH RePORTER · NIH RePORTER 11036694 (opens the source filing in a new tab)
Grant
R00 · $249k · non-dilutive
Feb 1, 2024
FRED HUTCHINSON CANCER CENTER · PI KANG, DONG-WOO · NCI · award ends Jun 30, 2028 · Harnessing Exercise to Enhance Immunity and Boost Immunotherapy Outcomes in Patients with Lung Cancer
NIH RePORTER · NIH RePORTER 11249260 (opens the source filing in a new tab)
Grant
R01 · $403k · non-dilutive
Aug 1, 2021
CASE WESTERN RESERVE UNIVERSITY · PI KANG, DAVID E · NINDS · award ends Jun 30, 2027 · Pathological Signatures of CHCHD10 Dysfunction in ADRDs
NIH RePORTER · NIH RePORTER 11115635 (opens the source filing in a new tab)
Trial
Study registered
Jan 1, 2015
Breast Cancer · COMPLETED · sponsor: Samsung Medical Center · Association of Breast Reconstruction Method With Long-term Risk of Psychiatric Disorders
ClinicalTrials.gov · NCT06981689 (opens the source filing in a new tab)
Trial
NA registered
Jul 1, 2010
Aortic Stenosis · COMPLETED · sponsor: Asan Medical Center · Early Surgery Versus Conventional Treatment in Very Severe Aortic Stenosis
ClinicalTrials.gov · NCT01161732 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75principal investigator KANG, DONGKYUN is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator KANG, DONGKYUN is named on this company's filings
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the grant record at 0.25same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Study registered, no phase assigned: Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial
3w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial
3w agoTrial recruitingSource (opens the source filing in a new tab)
NIH R00 · $0.2M · Harnessing Exercise to Enhance Immunity and Boost Immunotherapy Outcomes in Patients with Lung Cancer
Jun 2025Grant renewalSource (opens the source filing in a new tab)
Study registered, no phase assigned: Early Surgery Versus Conventional Treatment in Very Severe Aortic Stenosis
Jun 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Early Surgery Versus Conventional Treatment in Very Severe Aortic Stenosis
Jun 2025Trial completedSource (opens the source filing in a new tab)
NIH R01 · $0.4M · Pathological Signatures of CHCHD10 Dysfunction in ADRDs
Jun 2025Grant renewalSource (opens the source filing in a new tab)
Study registered, no phase assigned: Association of Breast Reconstruction Method With Long-term Risk of Psychiatric Disorders
May 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Association of Breast Reconstruction Method With Long-term Risk of Psychiatric Disorders
May 2025Trial completedSource (opens the source filing in a new tab)
NIH K01 · $0.2M · Understanding the neural markers of incentive salience for alcohol: the role of context in brain-behavior relationships
May 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.4M · Non-invasive, quantitative microscopic biomarkers for chemotherapy-induced peripheral neuropathy
Feb 2025New grantSource (opens the source filing in a new tab)
NIH R41 · $0.4M · Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
Jan 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.4M · Probe-Based Light Sheet Microscopy (pLSM) for Screening of Anal Cancer
Jan 2025New grantSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

NA registered

K01 · $165k · non-dilutive

R01 · $391k · non-dilutive

R41 · $400k · non-dilutive

R01 · $351k · non-dilutive

R00 · $249k · non-dilutive

R01 · $403k · non-dilutive

Study registered

NA registered